A carregar...

Benefit–Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis

Since the approval of fingolimod, several selective sphingosine-1-phosphate receptor modulators have entered clinical development for multiple sclerosis. However, side effects can occur with sphingosine-1-phosphate receptor modulators. By considering short-term data across the drug class and longer...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Drugs
Main Authors: Comi, Giancarlo, Hartung, Hans-Peter, Bakshi, Rajesh, Williams, Ian M., Wiendl, Heinz
Formato: Artigo
Idioma:Inglês
Publicado em: Springer International Publishing 2017
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5661009/
https://ncbi.nlm.nih.gov/pubmed/28905255
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-017-0814-1
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!